biOasis receives final report on Collaborative Research project from UBC

biOasis Technologies Inc. (TSX-V:BTI) has received a final report detailing results achieved within the Collaborative Research project with The University of British Columbia (UBC) that was announced by the Company on June 2, 2009. The report indicates that p97 (see About Transcend™ below) was more readily transported across the blood-brain barrier and accumulated to a significantly greater degree in brain tissue than did the anti-amyloid β IgG that was used as an experimental control. Further, it was observed that p97 accumulated in the brain more rapidly than IgG and to a much higher degree that has been reported previously. It was also demonstrated that the primary route of elimination of p97 from the body was via the kidney.

The objective of this research project was to compare the ability of different formulations of p97 to move across the blood-brain barrier in animal models. The closer examination of transport, kinetics and bio-distribution of species-specific p97 more closely reflects that which is expected with human p97 thus supporting the potential for p97 as a drug delivery vehicle.

"These results confirm past findings and support the development of p97 as Transcend™", says Rob Hutchison, President & CEO of biOasis . "The Company is in the process of initiating the Transcend™ program, in which drugs will be attached and moved across the blood-brain barrier ("BBB"). By enabling drugs that are currently unable to cross the BBB to enter the brain, biOasis will help to address significant medical challenges with the potential to create highly valuable assets for its shareholders". The Company is also anticipating results from its Cognitest™ program which if positive will enable the initiation of assay validation using human serum samples in the near future.